When does the label say to call your doctor?
From the Patient Information that comes with Imcivree:
- An erection lasting longer than 4 hours: get emergency medical help right away.
- New or worse symptoms of depression, suicidal thoughts or behaviors, or unusual changes in mood or behavior: you or a caregiver should call your healthcare provider right away.
- Swelling of the face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, or a rapid heartbeat: stop taking Imcivree and get medical help right away.
- With acquired HO and adrenal insufficiency, changes in tiredness, lack of energy, mental status or dizziness, or fever or signs of infection: call your healthcare provider.
- With acquired HO and diabetes insipidus, changes in fluid intake or urine output, confusion, lethargy, or nausea and vomiting: contact your healthcare provider.
What are the most common Imcivree side effects?
These are the label's own numbers from the Adverse Reactions section. Where the label compares with placebo (a dummy treatment), both columns are shown, so you can see how much more often a reaction happened on Imcivree.
Randomized placebo-controlled trial of 142 people aged 4 and older with acquired HO: a 4- to 8-week dose titration, then 52 weeks of treatment. (1) Includes skin hyperpigmentation, skin discoloration, nail pigmentation, freckles and pigmentation disorder. (2) Includes headache and migraine. (3) New moles and darkening or growth of existing moles.
Show all 10 reactionsHide table
| Adverse reaction | IMCIVREE (N=94) % | Placebo (N=48) % |
|---|---|---|
| Skin hyperpigmentation (1) | 58 | 10 |
| Nausea | 55 | 25 |
| Vomiting | 38 | 19 |
| Headache (2) | 37 | 31 |
| Melanocytic naevus (3) | 15 | 6 |
| Constipation | 12 | 6 |
| Dizziness | 12 | 4 |
| Oropharyngeal pain | 11 | 4 |
| Gastroenteritis | 9 | 2 |
| Ear infection | 5 | 0 |
Show the label table (11 rows)Hide table
| Adverse reaction | IMCIVREE-treated Patients N = 43 % |
|---|---|
| Skin hyperpigmentation (2) | 63 |
| Injection site reactions (3) | 51 |
| Nausea | 26 |
| Spontaneous penile erection (4) | 25 |
| Vomiting | 19 |
| Diarrhea | 14 |
| Melanocytic nevus (5) | 14 |
| Headache | 7 |
| Skin striae | 7 |
| Aggression | 5 |
| Fatigue | 5 |
43 people with BBS treated with at least 1 dose. This period had no placebo column; in the earlier 14-week placebo-controlled part, skin darkening was 67% vs 0% and vomiting 11% vs 0%. (2) Includes skin hyperpigmentation, hair color changes and melanoderma. (3) Includes injection-site redness, itching, hardening, pain, bruising, swelling, reaction, bleeding, irritation and mass. (4) n = 20 male patients. (5) New moles, larger moles and darkening of existing moles.
Show the label table (28 rows)Hide table
| Adverse reaction | IMCIVREE-treated Patients N = 27 % |
|---|---|
| Injection site reaction (1) | 96 |
| Skin hyperpigmentation (2) | 78 |
| Nausea | 56 |
| Headache | 41 |
| Diarrhea | 37 |
| Abdominal pain (3) | 33 |
| Back pain | 33 |
| Fatigue | 30 |
| Vomiting | 30 |
| Depression (4) | 26 |
| Upper respiratory tract infection | 26 |
| Spontaneous penile erection (5) | 23 |
| Arthralgia | 19 |
| Asthenia | 19 |
| Melanocytic nevus (6) | 19 |
| Dizziness | 15 |
| Dry mouth | 15 |
| Dry skin | 15 |
| Insomnia | 15 |
| Vertigo | 15 |
| Alopecia | 11 |
| Chills | 11 |
| Constipation | 11 |
| Influenza-like illness | 11 |
| Muscle spasm | 11 |
| Pain in extremity | 11 |
| Rash | 11 |
| Suicidal ideation | 11 |
Two 52-week open-label trials of 27 people; no placebo group. (1) Includes redness, itching, swelling, pain, hardening, bruising, hypersensitivity, hematoma, nodule and discoloration at the injection site. (2) Includes skin hyperpigmentation, pigmentation disorders, skin and gum discoloration. (3) Abdominal pain and upper abdominal pain. (4) Includes depressed mood. (5) n = 13 male patients. (6) New moles, larger moles and darkening of existing moles.
Other numbers in the Adverse Reactions section
- Section 6.1In acquired HO (Trial 1): spontaneous or more frequent erections 7% vs 4% on placebo; serious acute adrenal insufficiency 5% vs none; in people who also had central diabetes insipidus, low sodium 6% vs 2% and high sodium 5% vs 4%.
- Section 6.1In children aged 2 to under 6 with POMC or LEPR deficiency or BBS (Trial 5, 12 children, open-label): spontaneous erections 8% and depressed mood 8%.
Show 2 more findingsShow fewer
- Section 8.4Children with BBS or POMC, PCSK1 or LEPR deficiency had more vomiting, skin darkening and new or darkening moles than adults with these conditions.
- Section 5.4Skin darkening happened in most people on Imcivree in trials and goes away when the medicine is stopped.
What serious risks does the Imcivree label warn about?
The Warnings and Precautions part of the label lists these. Each line gives the label's heading and what it means in plain words.
- Section 5.1Sexual arousal changes. Spontaneous erections and more frequent erections in males, and sexual reactions in females, have occurred. An erection lasting longer than 4 hours needs emergency medical care.
- Section 5.2Depression and suicidal thoughts. Depression and suicidal thoughts have occurred. People with a past history may be at higher risk. People are watched for new or worse depression, suicidal thoughts or unusual mood changes, and stopping Imcivree may be considered.
- Section 5.3Serious allergic reactions. Serious allergic reactions, including anaphylaxis, have been reported, usually within minutes to hours of an injection. If one happens, Imcivree is stopped and medical help sought promptly.
- Section 5.4Skin darkening and moles. Imcivree can darken the skin, darken existing moles and cause new moles because of how it works. A full-body skin exam is done before starting and periodically during treatment.
Show 2 more risksShow fewer
- Section 5.5Adrenal insufficiency in acquired HO. In people with acquired HO and secondary adrenal insufficiency, serious acute adrenal insufficiency was reported in 5% on Imcivree and none on placebo. These people are watched for its signs.
- Section 5.6Sodium imbalance in acquired HO with diabetes insipidus. Both low and high blood sodium were reported. In people with acquired HO and central diabetes insipidus, sodium is checked with changes in fluid intake and hydration, and their diabetes insipidus treatment adjusted as needed.
Does Imcivree have a boxed warning?
No. The current Imcivree label has no boxed warning.
How do I keep track of side effects in Dose Track?
Dose Track has a side-effect log. Each entry records the symptom, a severity (none, mild, moderate, severe or life-threatening), the date and an optional note, and can be tied to a specific dose or logged on its own.
Read moreRead less
The history screen shows what you logged over time, which makes it easier to tell your prescriber when a reaction started and whether it is easing. The app records what you enter; it does not judge whether a symptom is serious. For anything on the label's call-your-doctor list, call your doctor.
Frequently asked questions
What is the most common side effect of Imcivree?
Skin darkening was among the most common in every trial: 58% vs 10% on placebo in acquired HO, 63% in BBS and 78% in POMC, PCSK1 or LEPR deficiency (section 6.1). Injection-site reactions and nausea were also very common.
Does Imcivree darken the skin permanently?
No. The label says the increase in skin pigmentation is reversible when the medicine is stopped (section 5.4). It can also darken existing moles and cause new ones, so a full-body skin exam is done before and during treatment.
Does Imcivree cause erections?
It can. Spontaneous erections were reported in 25% of males with BBS and 23% with POMC, PCSK1 or LEPR deficiency, and 7% vs 4% on placebo in acquired HO (section 6.1). An erection lasting longer than 4 hours needs emergency care (section 5.1).
Does Imcivree cause nausea?
Yes. Nausea was reported by 55% vs 25% on placebo in acquired HO, 26% in BBS and 56% in POMC, PCSK1 or LEPR deficiency (section 6.1). The label says to watch for stomach side effects while starting and raising the dose (sections 2.2, 2.3).
Related pages
- Imcivree dosing schedule from the same label
- Missed a dose of Imcivree? What the label says
- Free reconstitution calculator
Show similar medicinesShow fewer
Side effects for similar medicines
- Contravenaltrexone and bupropion
- Diethylpropiondiethylpropion hydrochloride
- Lomairaphentermine hydrochloride
- Phendimetrazinephendimetrazine tartrate
- Qsymiaphentermine and topiramate
- Xenicalorlistat
See also
- Setmelanotide: who it is for, label dosing and half-life
- How to store Imcivree (setmelanotide)
- Actoplus Met side effects
- Actos side effects
- Admelog side effects
Track it in Dose Track: GLP-1 tracker, TRT tracker or peptide tracker.
Sources
- IMCIVREE (setmelanotide) injection, for subcutaneous use, prescribing information and Patient Information. Rhythm Pharmaceuticals. DailyMed, version published April 2, 2026. DailyMed setid 70c3ccf7-4df0-4c75-ba07-fede9970c8d9
What Imcivree is approved forHide
Imcivree is approved to reduce excess body weight and keep it off long term in people 4 and older with acquired hypothalamic obesity (HO), and in people 2 and older with obesity due to Bardet-Biedl syndrome (BBS) or POMC, PCSK1 or LEPR deficiency confirmed by genetic testing (section 1). The label says it is not expected to work for general obesity or other types of obesity (section 1.1).
This page is what the FDA label says, in plain words. It is not medical advice. Follow your prescriber, and ask them or your pharmacist about anything here.
All side-effect pages · Dosing schedules · Missed dose guides · Compound guides